Molecular Regulation of Phosphate Metabolism by Fibroblast Growth Factor-23-Klotho System

Advances in Chronic Kidney Disease

Volumn 18, Issue 2, 2011, Pages 91-97

  Cheng, Chung Yi ^a   Kuro o, Makoto ^a   Razzaque, Mohammed S ^a  

^a HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

Author keywords

Calcium; FGF23; Klotho; NaPi; PTH; Vitamin D

Indexed keywords

DENTIN MATRIX PROTEIN 1; FIBROBLAST GROWTH FACTOR 23; KERATINOCYTE GROWTH FACTOR; KLOTHO PROTEIN; MATRIX EXTRACELLULAR PHOSPHOGLYCOPROTEIN; SECRETED FRIZZLED RELATED PROTEIN 4;

CHRONIC KIDNEY DISEASE; HUMAN; NONHUMAN; ONCOGENIC OSTEOMALACIA; PHOSPHATE METABOLISM; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW; X LINKED HYPOPHOSPHATEMIC RICKETS;

ABSORPTION; FIBROBLAST GROWTH FACTORS; GENE EXPRESSION REGULATION; GLUCURONIDASE; HOMEOSTASIS; HUMANS; KIDNEY TUBULES, PROXIMAL; PHOSPHATES; RENAL INSUFFICIENCY, CHRONIC; SODIUM-PHOSPHATE COTRANSPORTER PROTEINS;

EID: 79952597190     PISSN: 15485595     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ackd.2010.11.007     Document Type: Review

References (72)

1. Iotti S., Lodi R., Gottardi G., Zaniol P., Barbiroli B. Inorganic phosphate is transported into mitochondria in the absence of ATP biosynthesis: an in vivo 31P NMR study in the human skeletal muscle. Biochem Biophys Res Commun 1996, 225:191-194.
2. Hutson S.M., Williams G.D., Berkich D.A., LaNoue K.F., Briggs R.W. A 31P NMR study of mitochondrial inorganic phosphate visibility: effects of Ca2+, Mn2+, and the pH gradient. Biochemistry 1992, 31:1322-1330.
3. Gaasbeek A., Meinders A.E. Hypophosphatemia: an update on its etiology and treatment. Am J Med 2005, 118:1094-1101.
4. Schaefer B., Schlosser K., Wuhl E., et al. Long-term control of parathyroid hormone and calcium-phosphate metabolism after parathyroidectomy in children with chronic kidney disease. Nephrol Dial Transplant 2010, 25:2590-2595.
5. Carter J.L., O'Riordan S.E., Eaglestone G.L., Delaney M.P., Lamb E.J. Bone mineral metabolism and its relationship to kidney disease in a residential care home population: a cross-sectional study. Nephrol Dial Transplant 2008, 23:3554-3565.
6. Razzaque MS. Osteocalcin: a pivotal mediator or an innocent bystander in energy metabolism? Nephrol Dial Transplant. In press. doi:. doi:10.1093/ndt/gfq1721.
7. Fukagawa M., Kazama J.J., Kurokawa K. Renal osteodystrophy and secondary hyperparathyroidism. Nephrol Dial Transplant 2002, 17(suppl 10):2-5.
8. Fulzele K., Riddle R.C., Digirolamo D.J., et al. Insulin receptor signaling in osteoblasts regulates postnatal bone acquisition and body composition. Cell 2010, 142:309-319.
9. Berndt T.J., Schiavi S., Kumar R. "Phosphatonins" and the regulation of phosphorus homeostasis. Am J Physiol Renal Physiol 2005, 289:F1170-F1182.
10. Cai Q., Hodgson S.F., Kao P.C., et al. Brief report: inhibition of renal phosphate transport by a tumor product in a patient with oncogenic osteomalacia. N Engl J Med 1994, 330:1645-1649.
11. Kumar R. Tumor-induced osteomalacia and the regulation of phosphate homeostasis. Bone 2000, 27:333-338.
12. White K.E., Evans W.E., O'Rlordan J.L.H., et al. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 2000, 26:345-348.
13. De Beur S.M., Finnegan R.B., Vassiliadis J., et al. Tumors associated with oncogenic osteomalacia express genes important in bone and mineral metabolism. J Bone Miner Res 2002, 17:1102-1110.
14. Razzaque M.S. The FGF23-Klotho axis: endocrine regulation of phosphate homeostasis. Nat Rev Endocrinol 2009, 5:611-619.
15. Berndt T., Craig T.A., Bowe A.E., et al. Secreted frizzled-related protein 4 is a potent tumor-derived phosphaturic agent. J Clin Invest 2003, 112:785-794.
16. Razzaque M.S., Lanske B. The emerging role of the fibroblast growth factor-23-klotho axis in renal regulation of phosphate homeostasis. J Endocrinol 2007, 194:1-10.
17. Rowe P.S., Kumagai Y., Gutierrez G., et al. MEPE has the properties of an osteoblastic phosphatonin and minhibin. Bone 2004, 34:303-319.
18. Shimada T., Urakawa I., Yamazaki Y., et al. FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem Biophys Res Commun 2004, 314:409-414.
19. Kuro-o M. Klotho as a regulator of fibroblast growth factor signaling and phosphate/calcium metabolism. Curr Opin Nephrol Hypertens 2006, 15:437-441.
20. Quarles L.D. Endocrine functions of bone in mineral metabolism regulation. J Clin Invest 2008, 118:3820-3828.
21. Shimada T., Hasegawa H., Yamazaki Y., et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 2004, 19:429-435.
22. Liu S., Tang W., Zhou J., et al. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 2006, 17:1305-1315.
23. Kuro-o M. Endocrine FGFs and Klothos: emerging concepts. Trends Endocrinol Metab 2008, 19:239-245.
24. Ohnishi M., Nakatani T., Lanske B., Razzaque M.S. Reversal of mineral ion homeostasis and soft-tissue calcification of klotho knockout mice by deletion of vitamin D 1alpha-hydroxylase. Kidney Int 2009, 75:1166-1172.
25. Razzaque MS. The dualistic role of vitamin D in vascular calcifications. Kidney Int. In press. doi:. doi:10.1038/ki.2010.1432.
26. Yamashita T., Yoshioka M., Itoh N. Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem Biophys Res Commun 2000, 277:494-498.
27. Itoh N., Ornitz D.M. Functional evolutionary history of the mouse Fgf gene family. Dev Dyn 2008, 237:18-27.
28. Kurosu H., Ogawa Y., Miyoshi M., et al. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 2006, 281:6120-6123.
29. Nakatani T., Sarraj B., Ohnishi M., et al. In vivo genetic evidence for klotho-dependent, fibroblast growth factor 23 (Fgf23) -mediated regulation of systemic phosphate homeostasis. FASEB J 2009, 23:433-441.
30. Kuro-o M., Matsumura Y., Aizawa H., et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997, 390:45-51.
31. Imura A, Iwano A, Tohyama O, et al. Secreted Klotho protein in sera and CSF: implication for post-translational cleavage in release of Klotho protein from cell membrane. FEBS Lett. 565:143-147.
32. Shimada T., Kakitani M., Yamazaki Y., et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 2004, 113:561-568.
33. DeLuca S., Sitara D., Kang K., et al. Amelioration of the premature aging-like features of Fgf-23 knockout mice by genetically restoring the systemic actions of FGF-23. J Pathol 2008, 216:345-355.
34. Urakawa I., Yamazaki Y., Shimada T., et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006, 444:770-774.
35. Nakatani T., Ohnishi M., Razzaque M.S. Inactivation of klotho function induces hyperphosphatemia even in presence of high serum fibroblast growth factor 23 levels in a genetically engineered hypophosphatemic (Hyp) mouse model. FASEB J 2009, 23:3702-3711.
36. Razzaque M.S. FGF23-mediated regulation of systemic phosphate homeostasis: is Klotho an essential player?. Am J Physiol Renal Physiol 2009, 296:F470-F476.
37. Razzaque M.S. Phosphate toxicity: new insights into an old problem. Clin Sci (Lond) 2011, 120:91-97.
38. Razzaque M.S. Therapeutic potential of klotho-FGF23 fusion polypeptides: WO2009095372. Expert Opin Ther Pat 2010, 20:981-985.
39. Bai X., Dinghong Q., Miao D., Goltzman D., Karaplis A.C. Klotho ablation converts the biochemical and skeletal alterations in FGF23 (R176Q) transgenic mice to a Klotho-deficient phenotype. Am J Physiol Endocrinol Metab 2009, 296:E79-E88.
40. Ichikawa S., Imel E.A., Kreiter M.L., et al. A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. J Clin Invest 2007, 117:2684-2691.
41. Ohnishi M., Razzaque M.S. Dietary and genetic evidence for phosphate toxicity accelerating mammalian aging. FASEB J 2010, 24:3562-3571. 10.1096/fj.1009-152488.
42. Ohnishi M., Nakatani T., Lanske B., Razzaque M.S. In vivo genetic evidence for suppressing vascular and soft-tissue calcification through the reduction of serum phosphate levels, even in the presence of high serum calcium and 1,25-Dihydroxyvitamin D levels. Circ Cardiovasc Genet 2009, 2:583-590.
43. Sitara D., Kim S., Razzaque M.S., et al. Genetic evidence of serum phosphate-independent functions of FGF-23 on bone. PLoS Genet 2008, 4. e1000154.
44. Razzaque M.S., Sitara D., Taguchi T., St-Arnaud R., Lanske B. Premature ageing-like phenotype in fibroblast growth factor 23 null mice is a vitamin-D mediated process. FASEB J 2006, 20:720-722.
45. Razzaque M.S., Lanske B. Hypervitaminosis D and premature aging: lessons learned from Fgf23 and Klotho mutant mice. Trends Mol Med 2006, 12:298-305.
46. Hu M.C., Shi M., Zhang J., et al. Klotho: a novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule. FASEB J 2010, 24:3438-3450.
47. Farrow E.G., Davis S.I., Summers L.J., White K.E. Initial FGF23-mediated signaling occurs in the distal convoluted tubule. J Am Soc Nephrol 2009, 20:955-960.
48. Chihara Y., Rakugi H., Ishikawa K., et al. Klotho protein promotes adipocyte differentiation. Endocrinology 2006, 147:3835-3842.
49. Kuro-o M. Klotho as a regulator of oxidative stress and senescence. Biol Chem 2008, 389:233-241.
50. Ben-Dov I.Z., Galitzer H., Lavi-Moshayoff V., et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest 2007, 117:4003-4008.
51. Tsujikawa H., Kurotaki Y., Fujimori T., Fukuda K., Nabeshima Y. Klotho, a gene related to a syndrome resembling human premature aging, functions in a negative regulatory circuit of vitamin D endocrine system. Mol Endocrinol 2003, 17:2393-2403.
52. Chang Q., Hoefs S., van der Kemp A.W., Topala C.N., Bindels R.J., Hoenderop J.G. The beta-glucuronidase klotho hydrolyzes and activates the TRPV5 channel. Science 2005, 310:490-493.
53. Cha S.K., Ortega B., Kurosu H., Rosenblatt K.P., Kuro-o M., Huang C.L. Removal of sialic acid involving Klotho causes cell-surface retention of TRPV5 channel via binding to galectin-1. Proc Natl Acad Sci U S A 2008, 105:9805-9810.
54. Cha S.K., Hu M.C., Kurosu H., Kuro-o M., Moe O., Huang C.L. Regulation of ROMK1 channel and renal K+ excretion by Klotho. Mol Pharmacol 2009, 76:38-46.
55. Bresler D., Bruder J., Mohnike K., Fraser W.D., Rowe P.S. Serum MEPE-ASARM-peptides are elevated in X-linked rickets (HYP): implications for phosphaturia and rickets. J Endocrinol 2004, 183:R1-R9.
56. Dobbie H., Unwin R.J., Faria N.J., Shirley D.G. Matrix extracellular phosphoglycoprotein causes phosphaturia in rats by inhibiting tubular phosphate reabsorption. Nephrol Dial Transplant 2008, 23:730-733.
57. Feng J.Q., Ward L.M., Liu S., et al. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet 2006, 38:1310-1315.
58. Carpenter T.O., Ellis B.K., Insogna K.L., Philbrick W.M., Sterpka J., Shimkets R. Fibroblast growth factor 7: an inhibitor of phosphate transport derived from oncogenic osteomalacia-causing tumors. J Clin Endocrinol Metab 2005, 90:1012-1020.
59. Lorenz-Depiereux B., Bastepe M., Benet-Pages A., et al. DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat Genet 2006, 38:1248-1250.
60. Larsson T., Nisbeth U., Ljunggren O., Juppner H., Jonsson K.B. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 2003, 64:2272-2279.
61. Koh N., Fujimori T., Nishiguchi S., et al. Severely reduced production of klotho in human chronic renal failure kidney. Biochem Biophys Res Commun 2001, 280:1015-1020.
62. Kazama J.J., Sato F., Omori K., et al. Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients. Kidney Int 2005, 67:1120-1125.
63. Vervloet MG, van Ittersum FJ, Buttler RM, Heijboer A, Blankenstein MA, Ter Wee PM. Effects of dietary phosphate and calcium intake on fibroblast growth factor-23. Clin J Am Soc Nephrol. In press.
64. Antoniucci D.M., Yamashita T., Portale A.A. Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. J Clin Endocrinol Metab 2006, 91:3144-3149.
65. Nishida Y., Taketani Y., Yamanaka-Okumura H., et al. Acute effect of oral phosphate loading on serum fibroblast growth factor 23 levels in healthy men. Kidney Int 2006, 70:2141-2147.
66. Gutierrez O.M., Mannstadt M., Isakova T., et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008, 359:584-592.
67. Hsu H.J., Wu M.S. Fibroblast growth factor 23: a possible cause of left ventricular hypertrophy in hemodialysis patients. Am J Med Sci 2009, 337:116-122.
68. Komaba H., Goto S., Fujii H., et al. Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. Kidney Int 2010, 77:232-238.
69. Hofman-Bang J., Martuseviciene G., Santini M.A., Olgaard K., Lewin E. Increased parathyroid expression of klotho in uremic rats. Kidney Int 2010, 78:1119-1127.
70. Canalejo R., Canalejo A., Martinez-Moreno J.M., et al. FGF23 fails to inhibit uremic parathyroid glands. J Am Soc Nephrol 2010, 21:1125-1135.
71. Razzaque M.S. Does FGF23 toxicity influence the outcome of chronic kidney disease?. Nephrol Dial Transplant 2009, 24:4-7.
72. Razzaque M.S. Can fibroblast growth factor 23 fine-tune therapies for diseases of abnormal mineral ion metabolism?. Nat Clin Pract Endocrinol Metab 2007, 3:788-789.